Lonza has signed a five year deal to provide exclusive biologics development and manufacturing services for biotech firms within Index Ventures portfolio.
Hospira says its biosimilar partnership with Celltrion is secure even if the South Korean manufacturer is acquired as several media reports have speculated.
Last year Octapharma filed the world’s first ‘truly human’ recombinant Factor VIII clotting protein for EMA review and invited BioPharma-Reporter.com to visit the Swedish site where it makes the haemophilia treatment using HEK cells.
Johnson & Johnson (J&J) has called on the US FDA to prevent biosimilars being given the same non-proprietary names as their original biologics, while the European Generics Association maintains the practice is “proven to be safe” and “supported...
Brad Pitt made himself sick to avoid a zombie virus in World War Z but, despite some real world precedents, he was lucky his gamble paid off according to virus experts we asked.
AstraZeneca has become the third Big Biopharma to strike a deal with Immunocore to license its Immune Mobilising Monoclonal T-Cell Receptor Against Cancer (ImmTAC) technology.
Good news for stem cell scientists this week with new data indicating that patients support the use of induced pluripotent stem cells (iPSC) in biopharmaceutical research if proper consent is obtained.
Crescendo Biologics has secured funding to develop a range of Ab fragment-based drugs using its genetically modified mouse platform, including a psoriasis treament that could rival blockbusters like Remicade and Humira.
Sartorius has confirmed it will make the Ambr microreactor technology it acquired with Tap Biosystems compatible with its own downstream processing systems.
Roche has teamed with Molecular Profiles to test if short protein sequences can be used to target conjugated cancer drugs when antibodies prove to large.
Technology firm Upfront Chromatography has exited the biopharmaceutical manufacturing market after selling its protein purification business to Therapure Biopharma.
Cellexus has launched a new bioreactor system that employs an air-based mixing system that is better at aerating cell cultures than rocking or large chamber systems.
The climate for biomanufacturing has changed according to Pfizer, which has set out to win more contracting work for its hormone plant in Sweden and says it will even consider making large molecule drugs for Big Pharma rivals.
Choosing the same biomanufacturing tech supplier for development and commercial systems cuts scale steps and reduces lead times according to Cobra Biologics.
Almac says it is in a unique position to offer Carbon-14 ADME radiolabeling for the growing antibody-drug conjugate (ADC) market and has already performed the service on a Pfizer candidate.
Researchers recently genetically engineered rice to produce high yields of an antibody that proved effective in a study to treat and prevent rotavirus-induced gastrointestinal symptoms in mice.
The European Commission (EC) has cleared Thermo Fisher’s acquisition of Life Technologies subject to certain divestitures including its media and sera for cell culture business.
Kadcyla has become the second antibody-drug conjugate (ADC) to be available in Europe, triggering a $5m milestone payment by Roche to technology partner Immunogen.
Parexel has seen small and mid-sized biopharma demand for development services decline in recent months according to an anaylst who attended the CROs presentation at the Jefferies Global Healthcare conference this week.
Biosimilar clinical trials are increasing but levels of physician oversight and regulatory decisions are still hurdles to overcome, say Parexel, PPD and Vince & Associates.
Unclear terms in US biosimilars laws and the high cost of filing with the Food and Drug Administration (FDA) has set the stage for legal battles according to a lawyer who spoke at AAPS this week.
Genentech has recommissioned plans to make a Californian facility the largest biologics plant worldwide after anticipated revenue drop from biosimilars did not materialise.
Bioinvent has been granted a US patent for its FIRST screening platform and says it is unique in selecting antibodies without any prior knowledge of target identities.
Orgenesis has partnered ATMI and established a subsidiary in Belgium in order to manufacture cells for clinical trials of its insulin-producing regenerative drug.
With more and more biopharmaceutical firms developing therapeutic antibodies public knowledge of these powerful molecules is increasing, which is good news given how badly they've been portrayed in films so far.
ADC Therapeutics and Five Prime Therapeutics have announced an exclusive license agreement for human antibodies directed to an undisclosed target expressed on the surface of various types of cancers.
A new vitamin E-based hydrogel technology could improve how cancer busting mAbs are delivered and help biopharmas cut costs according to developer IBM.
Pfenex has selected Paragon Bioservices to manufacture its Recombinant Protective Antigen (rPA) for an anthrax vaccine as it enters Phase I clinical trials.
